Conditions: Chronic Kidney Disease
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 7
Healthy volunteers: no

Brief summary:
This study is not intended to treat anemia of chronic kidney disease but to determine the safety of the study drug, LY3113593.

The study will also evaluate how much of the study drug gets into the blood stream, how long it takes the body to remove the study drug, and what effect the study drug has on the body.

The study consists of up to three parts. Participants may only enroll in one part. Participants will receive up to four injections of LY3113593 or placebo into a vein. The study will last up to about 26 weeks including screening and follow-up.

Detailed description:

Arms:
arm 1: Escalating doses of LY3113593 administered by intravenous (IV) infusion once every 4 weeks (Q4W) on (Day 1 and 29) in part A. arm 2: 0.9% saline, administered by intravenous (IV) infusion once Q4W (Day 1 and 29) in part A.

Interventions: intervention 1: LY3113593 intervention 2: Placebo
Intervention descriptions: intervention 1: Administered by slow intravenous (IV) infusion. intervention 2: Administered by slow intravenous (IV) infusion.

Protocol document: